• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    23Andme Holding Co. (NQ: ME )

    3.160 -0.070 (-2.17%)
    Streaming Delayed Price Updated: 12:35 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 278,754
    Open 3.200
    Bid (Size) 3.140 (3)
    Ask (Size) 3.170 (10)
    Prev. Close 3.230
    Today's Range 2.985 - 3.210
    52wk Range 2.655 - 20.40
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
    From 23andMe, Inc.
    Via GlobeNewswire
    Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
    23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives. 
    Via Benzinga

    Performance

    YTD
    -82.61%
    -82.61%
    1 Month
    -34.85%
    -34.85%
    3 Month
    -49.08%
    -49.08%
    6 Month
    -68.99%
    -68.99%
    1 Year
    -82.03%
    -82.03%

    More News

    Read More
    23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 12, 2024
    Via Benzinga
    Earnings Outlook For 23andMe Holding
    Via Benzinga
    23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
    From 23andMe, Inc.
    Via GlobeNewswire
    CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe to Report Q2 FY2025 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Regains Compliance With Nasdaq Listing Requirements
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Appoints Three New Independent Directors to Board
    From 23andMe, Inc.
    Via GlobeNewswire
    ASML's Latest Chapter in the Semiconductor Story
    Via The Motley Fool
    23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
    From 23andMe, Inc.
    Via GlobeNewswire
    Author Alok Sama on OpenAI, Bubbles, and When to Sell
    Via The Motley Fool
    23andMe Announces Completion of 1-for-20 Reverse Stock Split
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Announces 1-for-20 Reverse Stock Split
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Announces Mathew Knowles as New Brand Ambassador
    From 23andMe, Inc.
    Via GlobeNewswire
    Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
    From 23andMe, Inc.
    Via GlobeNewswire
    Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time
    Via Benzinga
    General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    Independent Directors of 23andMe Resign from Board
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
    From 23andMe, Inc.
    Via GlobeNewswire
    One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
    From 23andMe, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.